evipedia.ai
← Back

Tribulus terrestris for Health & Longevity

Evidence Review created on 11/01/2026 using AI4L / Opus 5.5

Also known as: Puncture Vine, Puncturevine, Caltrop, Goathead, Gokshura, Gokhru, Bai Ji Li, Ci Ji Li, Fructus Tribuli, Khar-i-khasak, Tribulus, Tribestan

Motivation

Tribulus terrestris (puncture vine, gokshura) is a low-growing flowering weed whose spiny fruit, leaves and stems are sold as an herbal supplement. Its extracts are rich in plant steroid compounds proposed to act on blood flow in sexual tissues or on male hormones. It draws interest from health-focused adults as a possible natural aid for sexual vitality, male hormone levels and metabolic health.

The plant has a long history in Indian and Chinese traditional medicine for urinary, sexual and circulatory complaints. A standardized extract was developed in Bulgaria in the late twentieth century, and the herb later became one of the most widely marketed ingredients in products sold as natural testosterone boosters for athletes and aging men. Small human trials, some run by groups with ties to manufacturers, have since put these traditional and marketing claims to the test.

This review examines what the human evidence shows about the benefits and harms of Tribulus terrestris for adults pursuing a longer, healthier life, how it is dosed in trials, and how product quality and monitoring bear on its use.

Benefits - Risks - Protocol - Conclusion

This section lists expert commentary and narrative reviews that give a high-level overview of Tribulus terrestris.

Rhonda Patrick’s FoundMyFitness covers Tribulus terrestris only in a chapter of about one minute, shared with shilajit and fenugreek, in a testosterone episode (FoundMyFitness episode), too brief to serve as an overview. Life Extension Magazine also mentions it in one sentence of its 2005 article on integrative management of erectile dysfunction (Life Extension Magazine article); the Life Extension protocol listed above is its more substantial treatment. No directly relevant content was found from Peter Attia, Chris Kresser or Lifespan.io; both web searches and on-site searches returned no article, episode or post on Tribulus terrestris.

Grokipedia

Tribulus terrestris

An encyclopedic overview of the plant’s botany, traditional uses, chemistry and supplement use, useful as general background before reading the clinical literature.

Examine

Tribulus terrestris benefits, dosage, and side effects

Examine’s evidence summary concludes that tribulus appears to reduce symptoms of sexual dysfunction in men and women without raising testosterone, and might modestly improve metabolic health.

ConsumerLab

No dedicated ConsumerLab article on Tribulus terrestris exists.

Systematic Reviews

This section lists systematic reviews and meta-analyses of Tribulus terrestris covering sexual function, testosterone, fertility and sport-related health markers.

No systematic review or meta-analysis addresses the principal risk, rare liver and kidney injury; safety appears only as a secondary adverse-event outcome in the reviews above.

Mechanism of Action

Tribulus terrestris extracts are complex mixtures. The fruit and aerial parts contain steroidal saponins (soap-like plant steroids), mainly furostanol types such as protodioscin and spirostanol types such as terrestrosin D, plus flavonoids and cinnamic acid amides; content varies several-fold with plant part and origin, per a review (Ștefănescu 2020).

  • Erectile tissue relaxation: In rabbits, eight weeks of oral extract increased relaxation of the corpus cavernosum (the spongy erectile tissue), attributed to more nitric oxide (NO, a gas that widens blood vessels) release (Adaikan 2000).
  • Competing androgen hypothesis: In castrated rats, extract raised prostate weight and erectile pressure, attributed to androgen (male sex hormone) increases (Gauthaman 2002). A randomized trial in young men found no change in testosterone or luteinizing hormone (LH, the pituitary signal that drives testosterone production) (Neychev 2005), favoring the non-hormonal vascular explanation in humans.
  • Blood pressure: In hypertensive rats, extract lowered blood pressure and tissue angiotensin-converting enzyme (ACE, the enzyme that makes the vessel-tightening hormone angiotensin II) activity (Sharifi 2003).
  • Blood sugar: Cinnamic acid amides inhibit α-glucosidase (the gut enzyme that frees glucose from starch) in vitro (Song 2016).
  • Pharmacology: No human pharmacokinetic (absorption and clearance) data exist. A related injected furostanol saponin had a half-life of about 25–29 minutes in rats, cleared through urine and bile (Cao 2010); oral terrestrosin D accumulated in rat liver and kidney (Sun 2022). Receptor selectivity and enzyme metabolism remain uncharacterized.

Historical Context & Evolution

Tribulus terrestris is a spiny weed found across warm regions of Europe, Asia, Africa and Australia. In Ayurveda the fruit (gokshura) was used for urinary complaints, kidney stones and low virility, while Traditional Chinese Medicine used the fruit (bai ji li) for headache, dizziness, itching and vitiligo (patchy loss of skin pigment), per a review (Ștefănescu 2020). Extracts of the aerial parts and fruit served as diuretic (urine-increasing), tonic and aphrodisiac remedies, per a systematic review (Qureshi 2014).

Modern interest grew from Bulgaria, where Sopharma markets a standardized extract, Tribestan, for sexual dysfunction (Kamenov 2017, a trial co-authored by a Sopharma employee); its hormonal rationale rested largely on animal studies, per the same review (Qureshi 2014). Chinese researchers tested a saponin preparation for angina (chest pain from reduced heart blood flow) (Wang 1990). Marketing then carried the herb into sports nutrition as a natural testosterone booster, as that review describes (Qureshi 2014).

Placebo-controlled trials changed the picture. Studies in resistance-trained men and rugby players found no strength or lean-mass advantage (Antonio 2000; Rogerson 2007), and a trial in young men found no testosterone rise (Neychev 2005). Attention shifted to sexual function, where the 180-man Sopharma-linked trial reported benefit (Kamenov 2017) and a smaller independent trial did not (Santos 2014). The hormonal rationale has weakened under repeated human testing, while the sexual-function question remains open because large independent trials are lacking.

Expected Benefits

High 🟩 🟩 🟩

Sexual Function in Men and Women ⚠️ Conflicted

Placebo-controlled trials from independent groups report better erectile or sexual-desire scores: Kamenov 2017 (Bulgaria, Sopharma-linked), GamalEl Din 2019 (Egypt), Akhtari 2014 (Iran) and Postigo 2016 (Brazil). The proposed mechanism in men is nitric-oxide-driven smooth-muscle relaxation rather than testosterone; women’s trials reported free testosterone rises (Vale 2018; de Souza 2016). A 30-day, 30-man randomized trial found no difference from placebo (Santos 2014), possibly too brief and small, and reviewers judge the evidence insufficient or very low certainty (Ho 2026; Martimbianco 2020). Net, small trials favor a modest benefit in mild-to-moderate dysfunction.

Magnitude: Abridged International Index of Erectile Function (IIEF-5, a 5–25 point questionnaire) scores 3.23 points higher than placebo (95% confidence interval, CI, the range likely to hold the true effect: 1.89–4.58) across pooled trials (Suharyani 2026); full IIEF 2.70 points higher than placebo (95% CI 1.40–4.01) in the largest trial (Kamenov 2017).

Medium 🟩 🟩

Blood Pressure Reduction

In a randomized, double-blind trial at India’s National Institute of Unani Medicine (Greco-Arabic traditional medicine), adults with prehypertension (blood pressure above normal but below the hypertension threshold) took 6 g/day of powdered fruit for two months (Siddiqui 2021). The proposed mechanism is reduced angiotensin-converting enzyme activity and a mild diuretic effect seen in rats. Evidence comes from this single trial; no independent replication exists.

Magnitude: Systolic/diastolic blood pressure fell 7.7/5.5 mmHg with tribulus versus 1.9/0.2 mmHg with placebo (between-group difference significant, P < 0.001, P being the probability the difference arose by chance; no CI reported) (Siddiqui 2021).

Blood Glucose and Cholesterol Lowering

In a randomized, placebo-controlled trial, 98 women with type 2 diabetes took 1,000 mg/day of hydroalcoholic extract for three months; fasting glucose, total cholesterol and low-density lipoprotein (LDL, the main artery-clogging cholesterol carrier) fell versus placebo, while triglycerides and high-density lipoprotein (HDL, protective cholesterol carrier) did not change (Samani 2016). A review of active men also found improved lipid profiles (Fernández-Lázaro 2022). Proposed mechanisms include α-glucosidase inhibition.

Magnitude: Fasting glucose went from 169.3 to 143.9 mg/dL with tribulus versus 146.8 to 151.1 mg/dL with placebo, and LDL from 102.9 to 86.2 versus 93.5 to 91.4 mg/dL (group means only, no between-group difference figure; baseline-adjusted P < .05) (Samani 2016).

Low 🟩

Testosterone Increase ⚠️ Conflicted

Rat data suggested androgen increases (Gauthaman 2002). In men, randomized trials and reviews found no rise (Neychev 2005; Morgado 2024); small rises appeared mainly in men with low testosterone (GamalEl Din 2019) and in one single-blind CrossFit trial (Fernández-Lázaro 2021). Net, the stronger contrary evidence outweighs the positive signal.

Magnitude: Total testosterone did not differ from placebo in pooled trials (Suharyani 2026; no pooled figure reported); rises of 60–70 ng/dL appeared only in two studies of men with low testosterone, per a systematic review (Vilar Neto 2025; within-group, not compared between groups).

Muscle Strength and Body Composition ⚠️ Conflicted

Placebo-controlled trials in trained men and rugby players found no strength or lean-mass advantage (Antonio 2000; Rogerson 2007). A single-blind CrossFit trial reported a bench-press gain only (Fernández-Lázaro 2021). Net, the contrary trials outweigh this isolated positive finding.

Magnitude: After eight weeks of training, bench-press endurance rose 3.1% with tribulus versus 28.4% with placebo, and leg-press endurance 28.6% in both groups (Antonio 2000; not compared between groups); strength and fat-free mass rose equally in both groups after five weeks, with no between-group difference (Rogerson 2007).

Sperm Parameters in Infertile Men ⚠️ Conflicted ⭕️ Not Central to Health & Longevity

This bears on male fertility rather than longevity. Six of seven studies in a systematic review reported better sperm count, motility or shape, mostly without control groups (Sanagoo 2019); a 30-man study found no change (Roaiah 2017). Net, the mostly uncontrolled positive signal remains unconfirmed.

Magnitude: Sperm concentration and motility rose significantly from baseline in 65 men with abnormal semen analysis (Salgado 2017; no control group); six of seven studies in a systematic review reported improvement, and the literature reports no pooled outcome figure (Sanagoo 2019).

Angina Relief in Coronary Heart Disease

In 406 Chinese patients treated with a purified tribulus saponin preparation, results were compared with 67 patients given another herbal medicine, not placebo (Wang 1990). The evidence is indirect: a saponin fraction rather than whole extract, without randomization or blinding.

Magnitude: Angina remission in 82.3% with tribulus saponins versus 67.2% with the comparator herbal preparation (P < 0.05) (Wang 1990).

Speculative 🟨

Exercise Recovery ⭕️ Not Central to Health & Longevity

This bears on athletic recovery. In CrossFit athletes, lactate dehydrogenase (a muscle-damage enzyme) and C-reactive protein (an inflammation marker) stayed lower than with placebo, where they rose (Fernández-Lázaro 2022); both are unvalidated biomarkers.

Kidney Stone Prevention

Traditional Ayurvedic use for urinary stones rests on lab data: extract fractions blocked crystal aggregation in synthetic urine (Sharma 2017). No human stone outcome has been studied; the basis is mechanistic only.

Atherosclerosis Protection

In mice prone to atherosclerosis (artery plaque buildup), extract shrank aortic plaque and lowered cholesterol and inflammatory signals (Yu-Qian 2025). No human cardiovascular outcome data exist; the basis is animal work only.

Benefit-Modifying Factors

  • Genetic polymorphisms: No study has examined gene variants that change response to tribulus; variants in nitric oxide or androgen-receptor genes are plausible modifiers but untested.
  • Baseline testosterone: Testosterone rose only in men with low baseline levels (late-onset hypogonadism, age-related testosterone deficiency); men with normal levels showed no change, per a systematic review (Vilar Neto 2025).
  • Severity of sexual dysfunction: Benefits were reported in mild-to-moderate erectile dysfunction (Kamenov 2017); severe, vascular-driven dysfunction has not been tested.
  • Sex differences: Women with low sexual desire before and after menopause reported improved desire and arousal with free testosterone rises (Vale 2018; de Souza 2016); men showed erectile rather than hormonal effects.
  • Pre-existing conditions: The largest trial enrolled men with hypertension, diabetes and metabolic syndrome (a cluster of high blood pressure, glucose and waist size) (Kamenov 2017); the glucose and blood pressure trials enrolled only people with diabetes or prehypertension, so effects in others are untested.
  • Age: Trials enrolled adults up to about 65 years and postmenopausal women (de Souza 2016); data beyond 70 are absent.
  • Product composition: Saponin content varies several-fold by plant part and origin, per a review (Ștefănescu 2020), so benefits from one standardized extract may not transfer to another.

Potential Risks & Side Effects

High 🟥 🟥 🟥

No risk reaches High: placebo-controlled trials show no excess adverse events, and the serious harms rest only on isolated case reports.

Medium 🟥 🟥

No risk reaches Medium: no controlled trial or comparative observational study has shown an adverse event occurring more often with tribulus than with placebo.

Low 🟥

Liver and Kidney Injury

Case reports describe severe hyperbilirubinemia (bilirubin buildup causing jaundice), acute kidney injury and seizures after tribulus use (Talasaz 2010; Ryan 2015; Mohy-Ud-Din 2024), one requiring dialysis (Freidoon 2025). The saponin terrestrosin D accumulates in rat liver and kidney (Sun 2022).

Magnitude: Not quantified in available studies. Only isolated case reports exist; no trial or cohort has measured incidence.

Gastrointestinal Discomfort ⚠️ Conflicted

Stomach cramps, nausea and reflux are listed in drug references (Operation Supplement Safety article; MSKCC About Herbs monograph). Placebo-controlled trials found adverse events no more frequent than with placebo (Kamenov 2017). Net, mild digestive upset may occur but has not exceeded placebo rates.

Magnitude: In a 45-woman postmenopausal trial, 3 participants on tribulus and 3 on placebo withdrew for side effects (de Souza 2016); adverse-event incidence did not differ from placebo in pooled trials (Suharyani 2026).

Priapism

Priapism (a painful erection lasting hours without sexual stimulation) occurred in a 36-year-old man after a tribulus supplement, requiring a surgical shunt (a channel created to drain trapped blood) and leaving lasting sexual dysfunction (Campanelli 2016). The proposed mechanism is excess nitric-oxide-driven erectile tissue relaxation.

Magnitude: Not quantified in available studies. Only a single case report exists.

Gynecomastia

Gynecomastia (benign enlargement of male breast tissue) developed in a young weight trainer using a tribulus product as a steroid alternative (Jameel 2004). In vitro, a water extract showed estrogen-like activity (Abudayyak 2015).

Magnitude: Not quantified in available studies. Only a single case report exists.

Blood Clot Events

Cerebral venous thrombosis (a clot in the brain’s draining veins) was reported after tribulus use (Liguori 2015). Three coronary stent thromboses (clots inside artery stents) occurred with a tribulus, oat and ginseng combination taken alongside clopidogrel (Vatankulu 2012); this evidence is indirect (a combination product).

Magnitude: Not quantified in available studies. Only case reports exist.

Ventricular Arrhythmia

A case series describes two men with ventricular fibrillation (a chaotic, life-threatening heart rhythm) and aborted sudden cardiac death (cardiac arrest reversed by resuscitation) while taking Tribulus terrestris as an androgen booster (Moey 2022). The authors propose that androgens can worsen inherited heart-rhythm disorders; causality is unproven.

Magnitude: Not quantified in available studies. Only case reports exist.

Speculative 🟨

Prostate-Specific Antigen Rise

In men with low testosterone, prostate-specific antigen (PSA, a prostate cancer screening marker) rose from 1.4 to 1.7 ng/mL on tribulus (GamalEl Din 2019). PSA is an unvalidated harm marker; no clinical outcome followed.

Genotoxicity

In vitro, a water extract caused frameshift mutations (DNA reading-frame errors) after metabolic activation in bacterial assays (Abudayyak 2015). No human data exist; the basis is laboratory assays only.

Risk-Modifying Factors

  • Genetic polymorphisms: No variant has been linked to tribulus toxicity; the mechanism of the reported liver and kidney injuries is unknown, so susceptibility genes cannot be identified.
  • Baseline liver and kidney function: The reported severe cases involved acute rises in bilirubin, liver enzymes or creatinine (Talasaz 2010; Mohy-Ud-Din 2024); pre-existing impairment would leave less reserve, an inference without direct data.
  • Sex differences: All reported serious cases (liver, kidney, priapism, gynecomastia) involved men, reflecting who uses the herb; women in trials reported no serious adverse events, per a systematic review (Martimbianco 2020).
  • Pre-existing conditions: Coronary stents on antiplatelet therapy (clot-preventing drugs), prior blood clots, hormone-sensitive cancers and kidney stones treated with high-dose decoctions (herbal water boiled from the plant) represent settings where the reported harms would be most consequential.
  • Age: Older men may show PSA rises that complicate prostate cancer screening (GamalEl Din 2019); rhabdomyolysis (muscle breakdown) occurred in a 71-year-old man also taking atorvastatin (Huff 2024).
  • Dose and duration: Operation Supplement Safety lists sleep disturbance, fatigue and elevated heart rate above 1,000 mg/day (Operation Supplement Safety article); case reports followed use lasting days to months.

Key Interactions & Contraindications

Documented interactions:

  • Antidepressants (citalopram, escitalopram, trazodone): A retrospective review of adverse-event reports attributed generalized pruritus (itching), galactorrhea (milk discharge from the breast) and psoriasis relapse to combined use (Siwek 2023); mechanism unclear. Mitigation: disclosure to the prescriber and stopping tribulus if these appear.
  • Doping tests: Five weeks of 450 mg/day did not change the urinary testosterone-to-epitestosterone ratio used in anti-doping testing (Rogerson 2007); no interaction found.

Theoretical interactions (inferred from mechanism, not studied in humans):

  • Statins (cholesterol-lowering drugs; atorvastatin, simvastatin, lovastatin): Proposed CYP3A4 (the main liver enzyme that breaks down many drugs) inhibition could raise statin levels; one case of rhabdomyolysis (muscle breakdown) occurred with atorvastatin (Huff 2024). Mitigation: prompt reporting of muscle pain; rosuvastatin or pravastatin bypass CYP3A4.
  • Antiplatelet drugs (clopidogrel, prasugrel): Inferred from possible interference with clopidogrel’s liver activation; stent thrombosis occurred with a tribulus-containing herbal combination (Vatankulu 2012). Avoid with coronary stents.
  • Anticoagulants (drugs that slow blood clotting; warfarin): Inferred from proposed CYP3A4 inhibition slowing warfarin clearance; a sudden INR (International Normalized Ratio, a clotting-time measure) rise, which raises bleeding risk, occurred with a tribulus, oat and ginseng combination (Turfan 2012). Mitigation: early INR checks.
  • Antihypertensives, including ACE inhibitors (blood-pressure drugs blocking angiotensin II production; lisinopril, enalapril): Additive blood pressure lowering from ACE inhibition (Sharifi 2003) risks low blood pressure and dizziness; mitigation: home blood pressure checks.
  • Diuretics (furosemide, hydrochlorothiazide) and lithium: Additive diuretic effect (MSKCC About Herbs monograph) could cause dehydration and, with lithium, raised lithium levels; mitigation: lithium level checks if combined.
  • Glucose-lowering drugs (metformin, sulfonylureas (drugs that make the pancreas release more insulin), insulin): Additive glucose lowering (Samani 2016) risks hypoglycemia (low blood sugar); mitigation: glucose checks during the first weeks.
  • PDE5 inhibitors (erectile dysfunction drugs that boost nitric oxide signaling; sildenafil, tadalafil): Additive erectile tissue relaxation could raise priapism risk; an erection persisting hours beyond stimulation needs emergency care per a urology society guideline whose members provide that care (Bivalacqua 2022).
  • P-glycoprotein substrates (digoxin, dabigatran): Saponins inhibit P-glycoprotein (a pump that expels drugs from cells) in vitro (MSKCC About Herbs monograph), potentially raising drug levels; mitigation: digoxin level checks.
  • Over-the-counter NSAIDs (non-steroidal anti-inflammatory drugs; ibuprofen, naproxen) and high-dose acetaminophen: Additive kidney or liver stress inferred from tribulus case reports; mitigation: limiting regular use.
  • Supplements with additive effects (yohimbe, L-arginine, berberine, garlic, beetroot nitrate, other testosterone boosters): Additive blood pressure, glucose or erectile effects and multi-ingredient liver burden; mitigation: not stacking several products.
  • Hormone therapy (testosterone, estrogen): Reported estrogen-like activity in vitro could confound hormone monitoring; mitigation: informing the prescribing clinician.

Populations who should avoid Tribulus terrestris:

  • Pregnancy and breastfeeding: Inferred from steroidal saponins with reported hormone-like activity and absent human safety data; no human data.
  • Liver or kidney disease: Inferred from case reports of severe liver and kidney injury in previously healthy men (Mohy-Ud-Din 2024); no source gives a threshold.
  • Coronary stents on dual antiplatelet therapy (two clot-preventing drugs): Based on human case reports of stent thrombosis with a tribulus-containing combination (Vatankulu 2012).
  • Prior priapism or sickle cell disease: Inferred from the priapism case report (Campanelli 2016) and the known priapism risk in sickle cell disease, per a urology society guideline whose members treat priapism (Bivalacqua 2022).
  • Hormone-sensitive cancers (prostate, breast): Inferred from PSA rises and in-vitro estrogen-like activity; no human outcome data.

Risk Mitigation Strategies

Doses and timings below follow common practice unless cited.

  • Baseline and repeat liver and kidney panel: Checking liver enzymes, bilirubin and creatinine before starting and at 4–8 weeks detects the liver and kidney injury described in case reports early.
  • Stopping at warning signs: Stopping at once with jaundice, dark urine or reduced urine output limits drug-induced liver injury; a gastroenterology society guideline, whose members provide the specialist care, advises referral for progressive jaundice (Chalasani 2021).
  • Liver enzyme stopping threshold: Stopping when alanine aminotransferase (an enzyme leaked by damaged liver cells) exceeds 3× normal with bilirubin above 2× limits drug-induced liver injury, a serious-injury pattern per a gastroenterology society guideline whose members treat it (Chalasani 2021).
  • Prolonged erection plan: A urology society guideline whose members provide the treatment classes an erection persisting hours beyond stimulation as an emergency (Bivalacqua 2022), limiting permanent damage from priapism; not combining with PDE5 inhibitors lowers the risk.
  • Statin and antiplatelet review: Reviewing statin and clopidogrel use with the prescriber before starting reduces the rhabdomyolysis and stent thrombosis risks reported in case reports.
  • Dose ceiling: Staying at or below 1,000 mg/day of extract avoids the range where sleep disturbance and elevated heart rate are reported (Operation Supplement Safety article).
  • PSA before and after: PSA testing in men over 45 before and after three months prevents a tribulus-related PSA rise from being misread in cancer screening.
  • Single-ingredient, third-party tested products: Certified single-ingredient products avoid hidden erectile dysfunction drugs found in sexual enhancement products (FDA sexual enhancement notifications) and the extra liver burden of multi-herb blends.
  • Time-limited courses: Courses limited to the 1–3 months tested in trials reduce exposure to unknown long-term liver, kidney and hormonal effects.

Therapeutic Protocol

Other parameters without a citation (timing, cycling, titration steps) reflect common practice.

  • Standardized extract for erectile function: 1,500 mg/day of Tribestan (six 250 mg tablets standardized to furostanol saponins, three doses after meals) for 12 weeks (Kamenov 2017).
  • Lower-dose regimens: 750 mg/day in women with low sexual desire for 120 days (de Souza 2016); 800 mg/day in two doses for 30 days in men, without benefit (Santos 2014).
  • Metabolic and blood pressure regimens: 1,000 mg/day hydroalcoholic extract for three months (Samani 2016); 6 g/day powdered fruit in three doses for two months, a Unani regimen (Siddiqui 2021).
  • Athletic regimens: 450 mg/day (Rogerson 2007) or 770 mg/day (Fernández-Lázaro 2021); neither improved overall strength or body composition, apart from one bench-press gain in the latter.
  • Competing approaches: Conventional care uses PDE5 inhibitors for erectile dysfunction; integrative practitioners and podcasters such as Andrew Huberman present tribulus among herbal libido aids (Huberman Lab episode). No trial compares them head-to-head.
  • Time of day: No study compared dosing times; trials gave doses with meals, which may reduce stomach upset.
  • Half-life: No human half-life is known; a related injected saponin had a half-life of about 25–29 minutes in rats (Cao 2010).
  • Single versus split dosing: Most trials split the daily dose into two or three doses (Kamenov 2017; Santos 2014), consistent with rapid clearance; one gave 450 mg once daily (Rogerson 2007).
  • Genetic polymorphisms: No pharmacogenetic data exist; no variant is known to alter dose choice.
  • Sex differences: Women’s trials used 750 mg/day (de Souza 2016); men’s trials ranged from 450 to 1,500 mg/day, with no sex-specific dose-finding.
  • Age: No trial tested age-specific dosing; the oldest groups studied were postmenopausal women on 750 mg/day (de Souza 2016) and men up to 65, and older adults more often take interacting statins and antiplatelet drugs.
  • Baseline biomarkers: In men, testosterone rose mainly in those with low baseline levels (GamalEl Din 2019); most trials in men with normal levels found no change, per a systematic review (Vilar Neto 2025).
  • Pre-existing conditions: Men with hypertension and diabetes were enrolled in the largest positive trial (Kamenov 2017); liver or kidney disease argues against use.

Discontinuation & Cycling

  • Short-term use: Tribulus is used as a short-term course; human trials lasted 1–4 months, and no data support lifelong use.
  • Withdrawal effects: No withdrawal effects have been reported after stopping in any trial.
  • Tapering: No tapering is needed; trials stopped abruptly without rebound effects.
  • Cycling: Bodybuilding practice cycles tribulus (e.g., several weeks on, one or more off) to preserve effect, but no study has tested tolerance or cycling.
  • Stopping for toxicity: Immediate discontinuation is the response to jaundice, dark urine, reduced urine output or a prolonged erection, as in the reported cases.

Sourcing and Quality

  • Plant part and origin: Fruit, leaves and whole-plant extracts differ; saponin and protodioscin content varies several-fold by part and geographic origin, per a review (Ștefănescu 2020).
  • Standardization: Labels stating saponin percentage (often 40–45%) and, ideally, protodioscin content are preferable; the most studied extract, Tribestan, is standardized to furostanol saponins (Kamenov 2017).
  • Hidden drugs: Products marketed for sexual enhancement are frequently found to contain undeclared sildenafil or tadalafil (FDA sexual enhancement notifications).
  • Third-party testing: NSF Certified for Sport or USP (United States Pharmacopeia) Verified seals indicate independent testing.
  • Fungal contamination: Toxin-producing Fusarium fungi making cell-damaging mycotoxins (fungal toxins) have been isolated from stored tribulus plant material (Abeywickrama 1992).
  • Brands: Tribestan (Sopharma) is the most studied product; Life Extension sells a 450 mg extract guaranteed to 40% saponins (Life Extension product page); examples, not endorsements.

Practical Considerations

  • Time to effect: Sexual-function benefits appeared after 4–12 weeks (Akhtari 2014; Kamenov 2017); blood pressure and glucose changes after two to three months (Siddiqui 2021; Samani 2016).
  • Common pitfalls: Expecting testosterone or muscle gains, using unstandardized or multi-ingredient “booster” blends, combining with statins or PDE5 inhibitors, and continuing despite jaundice or dark urine.
  • Regulatory status: In the United States, tribulus is sold as a dietary supplement, not an approved drug; it is not on the Department of Defense prohibited supplement ingredient list (Operation Supplement Safety article).
  • Cost: Extracts are inexpensive and widely available; generic PDE5 inhibitors are also low-cost, so payers have little financial incentive to favor either.

Interaction with Foundational Habits

  • Sleep: Direct, blunting at high doses: sleep disturbance is reported above 1,000 mg/day (Operation Supplement Safety article); mechanism unknown. Keeping doses lower and taking the last dose with the evening meal or earlier is a practical precaution.
  • Nutrition: Indirect, potentiating: glucose and cholesterol lowering (Samani 2016) may add to a fiber-rich diet low in rapidly absorbed sugars; no nutrient depletion is known. Taking doses with meals, as in trials, may reduce stomach upset.
  • Exercise: None: tribulus neither enhances nor blunts strength or lean-mass gains from resistance training (Rogerson 2007); no timing around workouts matters for those outcomes.
  • Stress management: None measured: cortisol (the main stress hormone) did not change versus placebo in trained athletes (Fernández-Lázaro 2021); any mood or libido benefit is indirect through sexual function.

Monitoring Protocol & Defining Success

Baseline testing before starting covers liver function (alanine aminotransferase, ALT, and aspartate aminotransferase, AST, enzymes released by damaged liver cells; total bilirubin), kidney function (creatinine with estimated glomerular filtration rate, eGFR, the calculated kidney filtering rate), blood pressure, fasting glucose with HbA1c (glycated hemoglobin, average glucose over three months), LDL cholesterol, a PSA for men over 45, and a validated sexual-function questionnaire such as the IIEF-5.

Ongoing monitoring follows a cadence of liver and kidney tests at 4–8 weeks, then every three months during continued use; blood pressure weekly at home for the first month; glucose and LDL at three months; PSA at three months in men; and the questionnaire at 4 and 12 weeks to judge response. Absence of improvement by 12 weeks defines non-response.

Biomarker Optimal Functional Range Why Measure It? Context/Notes
ALT and AST ALT 7–56 U/L; AST 10–40 U/L (standard reference range) Safety check: rises signal liver injury; use stops if rising Fasting not required; pair with bilirubin; progressive jaundice warrants specialist care per a gastroenterology society guideline whose members provide it (Chalasani 2021)
Total bilirubin 0.1–1.2 mg/dL (standard reference range) Safety check: jaundice dominated reported cases Pair with ALT and AST; check urine color between tests
Creatinine and eGFR Creatinine 0.7–1.3 mg/dL in men, 0.6–1.1 mg/dL in women; eGFR 90 mL/min/1.73 m² or higher (standard reference range) Safety check: kidney injury reported; use stops if rising Heavy exercise or high meat intake in the prior 24 hours can raise creatinine
Blood pressure Below 130/80 mmHg (Whelton 2018 guideline target) Expected to change: may fall Cited: Whelton 2018, a cardiology societies’ guideline whose members treat hypertension; the same guideline classifies below 120/80 mmHg as normal (conventional reference); seated, home readings averaged over a week
Fasting glucose and HbA1c Fasting glucose 70–99 mg/dL; HbA1c 4.0–5.6% (standard reference range) Expected to change: may fall, mainly in diabetes Fast 8–12 hours; watch for low glucose with diabetes drugs
LDL cholesterol No established target; track change from own baseline Expected to change: may fall Fasting improves accuracy; pair with total cholesterol, HDL and triglycerides
PSA (men) 0–4.0 ng/mL (standard reference range) Safety check: rose in one trial (GamalEl Din 2019); a rise changes screening interpretation Ejaculation or cycling in the prior 48 hours can raise PSA
IIEF-5 score (men) 22–25, the no-dysfunction band (Rosen 1999) Expected to change: primary efficacy marker Cited: Rosen 1999; no laboratory reference range applies; a score of 21 or less indicates erectile dysfunction in the same source

Qualitative markers:

  • Erection quality, sexual desire and satisfaction
  • Sleep quality and onset, especially at doses near 1,000 mg/day
  • Energy levels and daytime fatigue
  • Digestive comfort after doses
  • Urine color, skin or eye yellowing, and urine output
  • Muscle pain or weakness when also taking a statin

Emerging Research

  • Male fertility trial: NCT06260007 is a phase 4, placebo-controlled trial of three tribulus products in 204 men with oligospermia (low sperm count), sponsored by manufacturer Herbarium. Its registered completion (August 2026) has passed; the record lists recruiting, without posted results. A positive result would raise the sperm item; a null one would weaken it.
  • Acute sprint trial: NCT07164547 tested a single 625 mg dose before sprint and anaerobic (short, all-out) power tests in 28 combat-sport athletes (crossover). It completed in August 2025 with no results posted. A positive result would suggest an acute performance effect; a null result would further weaken ergogenic (performance-enhancing) claims.
  • Recreational runners trial (no NCT ID): A placebo-controlled trial of 1,000 mg/day for two weeks on inflammation, oxidative stress and performance (IRCT20150205020965N8; Nejati 2022) lists recruitment complete since 2021, with no results on PubMed as of 10/31/2026. A positive result would support the recovery item; a null one would weaken it.
  • Independent erectile-function replication: Pooled positive results (Suharyani 2026) contrast with a meta-analysis judging tribulus evidence insufficient (Ho 2026); larger trials independent of manufacturers could confirm or overturn the main benefit.
  • Saponin toxicology: Rat work showing terrestrosin D accumulation and reversible liver and kidney toxicity (Sun 2022) points to human dose-ranging and pharmacovigilance (adverse-event surveillance) studies that could strengthen the risk case.
  • Skin pigmentation: Tribuloside, a tribulus flavonoid, increased melanin production in human skin samples and zebrafish (Cao 2024), supporting the traditional Chinese use for vitiligo; human trials are absent.

Conclusion

Tribulus terrestris is a traditional Indian and Chinese herb, now sold mainly as a supplement for sexual vitality and as a “natural testosterone booster.” For health-focused adults, the human evidence separates these claims sharply.

The most consistent signal is a modest improvement in sexual function, seen in small studies comparing the herb with a placebo in men with mild-to-moderate erection problems and in women with low sexual desire. That signal is fragile: the studies are small and short, quality is often low, the largest was co-authored by staff of the leading product’s maker, and some independent studies and reviews found no clear benefit. Early studies also point to lower blood pressure, blood sugar and cholesterol, each resting on one study. The testosterone claim fares poorly. Repeated human testing found no meaningful rise except perhaps in men who start with low levels, and the herb does not build strength or muscle.

On the risk side, side effects in controlled studies were no more common than with a placebo, but rare case reports describe serious liver and kidney injury, a prolonged painful erection, breast tissue growth in a man, blood clots and dangerous heart rhythms. Possible interactions with cholesterol-lowering drugs and clot-preventing drugs are a particular concern for older users. Product contents vary widely, and sexual-enhancement products are sometimes found to contain undeclared drugs.

The evidence base is thin, short-term and partly industry-linked, leaving uncertainty about the size of the sexual-function benefit and how often serious harm occurs.

Top - Benefits - Risks - Protocol